Teva Defends Vincristine Discontinuation Decision
Insists It Is Not Responsible For US Shortages
Amid emotive US mainstream media coverage of shortages of the children’s cancer treatment vincristine, Teva insists it is not to blame after discontinuing production of the chemotherapy agent.
You may also be interested in...
As the response to another wave of COVID-19 infections continues, fill rates of critical medicines such as methylprednisolone are dropping. But experts say the answer is not to concentrate manufacturing in US facilities, which could lead to further risks if US supply is disrupted.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.